ArticleBMC biotechnology2026
Synthesis and application of exopolysaccharide-selenium nanocomposite produced by Pseudoduganella armeniaca ZMN-3.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study investigated the antioxidant and anticancer activities of selenium nanoparticles stabilized by exopolysaccharides from Pseudoduganella armeniaca ZMN-3 (EPS‑SeNPs). The synthesized EPS‑SeNPs had an average size of 145 nm and were thoroughly characterized. In vitro antioxidant assays revealed that at 4 mg/mL, EPS‑SeNPs scavenged 86.49 ± 0.53% of DPPH radicals, 82.96 ± 0.32% of ABTS radicals, and 36.41 ± 0.77% of hydroxyl radicals. The reducing power assay showed that, at the same concentration, EPS‑SeNPs exhibited an absorbance value of 1.28 ± 0.029, which was higher than that of the other groups. The EPS‑SeNPs composite exhibited pronounced time- and concentration-dependent antiproliferative effects against the two selected cancer cell lines, MCF‑7 and SMMC. After 48 h of treatment at the highest concentration (250 µg/mL), the inhibition rates reached 52.88% for SMMC cells and 54.41% for MCF-7 cells. This effect was significantly stronger than that of EPS or SeNPs alone, indicating a marked enhancement. Cytokine analysis further revealed that even at a low concentration (31.25 µg/mL), a measurable effect was observed. The levels of TNF‑α released by SMMC and MCF‑7 cells reached their highest values at the high concentration of 250 µg/mL, namely 344.79 pg/mL and 132.6 pg/mL, respectively. This promoting effect exceeded that of the positive control (LPS group) and was notably stronger than the effects of SeNPs or EPS alone, with the enhancement being particularly prominent in SMMC cells. Collectively, EPS-SeNPs exhibit both antioxidant and in vitro anti-tumor activity, warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.